同源康医药-B(02410)：艾多替尼一线治疗晚期非小细胞肺癌脑转移的关键性研究最新成果以LBA形式于2026年ASCO年会上公布

智通财经05-31

智通财经APP讯，同源康医药-B(02410)发布公告，本公司自主研发的甲磺酸艾多替尼片 (TY-9591)对比奥希替尼一线治疗表皮生长因子受体(EGFR)突变非小细胞肺癌 (NSCLC)脑转移患者关键II期ESAONA研究的期中分析结果，已于2026年美国临床肿瘤学会(ASCO)年会上以最新突破性摘要“LBA”口头报告形式公布。EGFR酪氨酸激酶抑制剂(TKI)给EGFR敏感突变NSCLC患者...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2639600214?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-31 18:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2639600214","market":"us","top_or_hot":-1,"title":"同源康医药-B(02410)：艾多替尼一线治疗晚期非小细胞肺癌脑转移的关键性研究最新成果以LBA形式于2026年ASCO年会上公布","media":"智通财经","content":"<div>\n<p>智通财经APP讯，同源康医药-B(02410)发布公告，本公司自主研发的甲磺酸艾多替尼片 (TY-9591)对比奥希替尼一线治疗表皮生长因子受体(EGFR)突变非小细胞肺癌 (NSCLC)脑转移患者关键II期ESAONA研究的期中分析结果，已于2026年美国临床肿瘤学会(ASCO)年会上以最新突破性摘要“LBA”口头报告形式公布。EGFR酪氨酸激酶抑制剂(TKI)给EGFR敏感突变NSCLC患者...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1448182.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>同源康医药-B(02410)：艾多替尼一线治疗晚期非小细胞肺癌脑转移的关键性研究最新成果以LBA形式于2026年ASCO年会上公布</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n同源康医药-B(02410)：艾多替尼一线治疗晚期非小细胞肺癌脑转移的关键性研究最新成果以LBA形式于2026年ASCO年会上公布\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-31 18:18 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1448182.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，同源康医药-B(02410)发布公告，本公司自主研发的甲磺酸艾多替尼片 (TY-9591)对比奥希替尼一线治疗表皮生长因子受体(EGFR)突变非小细胞肺癌 (NSCLC)脑转移患者关键II期ESAONA研究的期中分析结果，已于2026年美国临床肿瘤学会(ASCO)年会上以最新突破性摘要“LBA”口头报告形式公布。EGFR酪氨酸激酶抑制剂(TKI)给EGFR敏感突变NSCLC患者...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1448182.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09939","symbol_name":"开拓药业-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1448182.html","article_id":"2639600214","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2639600214","pubTimestamp":1780222714,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，同源康医药-B 发布公告，本公司自主研发的甲磺酸艾多替尼片 对比奥希替尼一线治疗表皮生长因子受体突变非小细胞肺癌 脑转移患者关键II期ESAONA研究的期中分析结果，已于2026年美国临床肿瘤学会年会上以最新突破性摘要“LBA”口头报告形式公布。ESAONA研究是一项开放标签、多中心、随机对照的关键II期临床研究，旨在评估艾多替尼对比奥希替尼一线治疗EGFR经典突变NSCLC脑转移患者的疗效和安全性。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","09939":"开拓药业-B","02410":"同源康医药-B","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"Tongyuankang Pharmaceutical-B (02410): The latest results of the key research of edotinib in the first-line treatment of brain metastasis from advanced non-small cell lung cancer were announced at the 2026 ASCO Annual Meeting in the form of LBA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1.5,"09939":1.5,"02410":1.5},"content_text":"智通财经APP讯，同源康医药-B(02410)发布公告，本公司自主研发的甲磺酸艾多替尼片 (TY-9591)对比奥希替尼一线治疗表皮生长因子受体(EGFR)突变非小细胞肺癌 (NSCLC)脑转移患者关键II期ESAONA研究的期中分析结果，已于2026年美国临床肿瘤学会(ASCO)年会上以最新突破性摘要“LBA”口头报告形式公布。EGFR酪氨酸激酶抑制剂(TKI)给EGFR敏感突变NSCLC患者带来了显著的生存期改善，但对于伴有严重威胁生命健康及生活质量的脑转移患者疗效有限。甲磺酸艾多替尼片是一款新型的第叁代EGFR-TKI，在两项早期临床研究(NCT04204473，NCT05146219)中展现出良好的颅内疗效和安全性。ESAONA研究是一项开放标签、多中心、随机对照的关键II期临床研究，旨在评估艾多替尼对比奥希替尼一线治疗EGFR经典突变NSCLC脑转移患者的疗效和安全性。纳入患者按照1:1的比例随机分配至艾多替尼组(160mg QD)或奥希替尼组 (80mg QD)，根据EGFR突变亚型(19Del或L858R)和颅内病灶数量(>3或≤3)分层。研究的主要终点包括盲态独立中心评估(BICR)依据RECIST v1.1判断的颅内客观缓解率(iORR)和颅内无进展生存期(iPFS)，次要终点包括研究者(INV)分别依据 RECIST v1.1和RANO-BM评估的iORR和iPFS，BICR和INV评估的ORR、PFS、颅内缓解持续时间(iDoR)、总生存期(OS)、安全性等。截至2025年12月15日(本次数据分析时间)，研究中位随访时间为19.12个月。两组共纳入224例患者(艾多替尼组111例，奥希替尼组113例)，两组之间基线数据均衡可比。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2639600214","isCrawlerRequest":true}